FIELD: medicine.
SUBSTANCE: group of inventions is intended for prevention or treatment of taupathy. Method employs 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-azetidine-3-ol or a salt thereof for preventing or treating taupathy. Said agent has action to increase amount of amyloid β protein in cerebrospinal fluid, to reduce amount of amyloid β protein in the brain or by reducing the amount of phosphorylated tau protein in the cerebrospinal fluid or in the brain. Taupathy is Alzheimer's disease, probable Alzheimer's disease, possible Alzheimer's disease, a preclinical stage of Alzheimer's disease, a prodromal stage of Alzheimer's disease, moderate cognitive impairment due to Alzheimer's disease or moderate cognitive impairment. Said agent is used in a patient, which demonstrates progress in increasing the amount of tau protein in the brain or passes the test in order to see the progress in increasing the amount of p-Tau in the brain.
EFFECT: using the group of inventions enables higher effectiveness of treating taupathy.
18 cl, 3 tbl, 3 ex, 5 dwg
